Matthew R Smith1, Dana E Rathkopf2, Peter F A Mulders3, Joan Carles4, Hendrik Van Poppel5, Jinhui Li6, Thian Kheoh7, Thomas W Griffin8, Arturo Molina9, Charles J Ryan10. 1. Department of Genitourinary Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Electronic address: smith.matthew@mgh.harvard.edu. 2. Department of Oncology and Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Urology, Radboud University Medical Centre, Nijmegen, The Netherlands. 4. Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain. 5. Department of Urology, University Hospitals of KU Leuven, Leuven, Belgium. 6. Department of Biostatistics Oncology, Janssen Research & Development, Raritan, New Jersey. 7. Department of Biostatistics and Programming, Janssen Research & Development, San Diego, California. 8. Department of WC Clinical Oncology, Janssen Research & Development, Los Angeles, California. 9. Department of Oncology, Janssen Research & Development, Los Angeles, California. 10. Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California.
Abstract
PURPOSE:Metastatic castration resistant prostate cancer primarily affects elderly men. In this post hoc analysis we investigated the safety and efficacy of abiraterone acetate in elderly (age 75 years or greater) and younger (less than 75 years) patient subgroups at the prespecified interim analysis (55% of total overall survival events) for the COU-AA-302 (Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer) trial. MATERIALS AND METHODS: Patients were stratified and randomized 1:1 to abiraterone acetate 1,000 mg plus prednisone/prednisolone 5 mg twice daily (abiraterone-prednisone) vs placebo plus prednisone/prednisolone 5 mg twice daily (prednisone alone). Co-primary end points were radiographic progression-free and overall survival. Median time to event and HR were estimated using the Kaplan-Meier method and a Cox model, respectively. RESULTS: A total of 350 elderly patients treated withabiraterone-prednisone had significant improvements in overall and radiographic progression-free survival vs those with prednisone alone (HR 0.71, 95% CI 0.53-0.96 vs HR 0.63, 95% CI 0.48-0.83), similar to 738 younger patients (HR 0.81, 95% CI 0.63-1.03 vs HR 0.49, 95% CI 0.40-0.59). All secondary end points favored the abiraterone-prednisone arm for both age subgroups. Specific adverse events with abiraterone-prednisone were similar between the age subgroups. Elderly patients in both treatment arms had higher rates of fluid retention and cardiac disorders than younger patients, although rates of dose reduction or treatment interruptions due to adverse events were low in both age subgroups. CONCLUSIONS:Abiraterone acetate demonstrated clinical benefit and was well tolerated in elderly and younger men with chemotherapy naïve, metastatic castration resistant prostate cancer. Thus, findings support it as a treatment option for elderly patients who may not tolerate other therapies with greater toxicity.
RCT Entities:
PURPOSE: Metastatic castration resistant prostate cancer primarily affects elderly men. In this post hoc analysis we investigated the safety and efficacy of abiraterone acetate in elderly (age 75 years or greater) and younger (less than 75 years) patient subgroups at the prespecified interim analysis (55% of total overall survival events) for the COU-AA-302 (Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer) trial. MATERIALS AND METHODS:Patients were stratified and randomized 1:1 to abiraterone acetate 1,000 mg plus prednisone/prednisolone 5 mg twice daily (abiraterone-prednisone) vs placebo plus prednisone/prednisolone 5 mg twice daily (prednisone alone). Co-primary end points were radiographic progression-free and overall survival. Median time to event and HR were estimated using the Kaplan-Meier method and a Cox model, respectively. RESULTS: A total of 350 elderly patients treated with abiraterone-prednisone had significant improvements in overall and radiographic progression-free survival vs those with prednisone alone (HR 0.71, 95% CI 0.53-0.96 vs HR 0.63, 95% CI 0.48-0.83), similar to 738 younger patients (HR 0.81, 95% CI 0.63-1.03 vs HR 0.49, 95% CI 0.40-0.59). All secondary end points favored the abiraterone-prednisone arm for both age subgroups. Specific adverse events with abiraterone-prednisone were similar between the age subgroups. Elderly patients in both treatment arms had higher rates of fluid retention and cardiac disorders than younger patients, although rates of dose reduction or treatment interruptions due to adverse events were low in both age subgroups. CONCLUSIONS:Abiraterone acetate demonstrated clinical benefit and was well tolerated in elderly and younger men with chemotherapy naïve, metastatic castration resistant prostate cancer. Thus, findings support it as a treatment option for elderly patients who may not tolerate other therapies with greater toxicity.
Authors: Karim Fizazi; Howard I Scher; Arturo Molina; Christopher J Logothetis; Kim N Chi; Robert J Jones; John N Staffurth; Scott North; Nicholas J Vogelzang; Fred Saad; Paul Mainwaring; Stephen Harland; Oscar B Goodman; Cora N Sternberg; Jin Hui Li; Thian Kheoh; Christopher M Haqq; Johann S de Bono Journal: Lancet Oncol Date: 2012-09-18 Impact factor: 41.316
Authors: Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono Journal: N Engl J Med Date: 2012-08-15 Impact factor: 91.245
Authors: Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor Journal: Lancet Date: 2010-10-02 Impact factor: 79.321
Authors: Peter F A Mulders; Arturo Molina; Michael Marberger; Fred Saad; Celestia S Higano; Kim N Chi; Jinhui Li; Thian Kheoh; Christopher M Haqq; Karim Fizazi Journal: Eur Urol Date: 2013-09-20 Impact factor: 20.096
Authors: Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544
Authors: Jean-Pierre Droz; Matti Aapro; Lodovico Balducci; Helen Boyle; Thomas Van den Broeck; Paul Cathcart; Louise Dickinson; Eleni Efstathiou; Mark Emberton; John M Fitzpatrick; Axel Heidenreich; Simon Hughes; Steven Joniau; Michael Kattan; Nicolas Mottet; Stéphane Oudard; Heather Payne; Fred Saad; Toru Sugihara Journal: Lancet Oncol Date: 2014-08 Impact factor: 41.316
Authors: Dana E Rathkopf; Matthew R Smith; Johann S de Bono; Christopher J Logothetis; Neal D Shore; Paul de Souza; Karim Fizazi; Peter F A Mulders; Paul Mainwaring; John D Hainsworth; Tomasz M Beer; Scott North; Yves Fradet; Hendrik Van Poppel; Joan Carles; Thomas W Flaig; Eleni Efstathiou; Evan Y Yu; Celestia S Higano; Mary-Ellen Taplin; Thomas W Griffin; Mary B Todd; Margaret K Yu; Youn C Park; Thian Kheoh; Eric J Small; Howard I Scher; Arturo Molina; Charles J Ryan; Fred Saad Journal: Eur Urol Date: 2014-03-06 Impact factor: 20.096
Authors: Badereddin Mohamad Al-Ali; Klaus Eredics; Stephan Madersbacher; Ingrid Schauer Journal: Wien Klin Wochenschr Date: 2018-10-15 Impact factor: 1.704
Authors: Fred Saad; Eleni Efstathiou; Gerhardt Attard; Thomas W Flaig; Fabio Franke; Oscar B Goodman; Stéphane Oudard; Thomas Steuber; Hiroyoshi Suzuki; Daphne Wu; Kesav Yeruva; Peter De Porre; Sabine Brookman-May; Susan Li; Jinhui Li; Shibu Thomas; Katherine B Bevans; Suneel D Mundle; Sharon A McCarthy; Dana E Rathkopf Journal: Lancet Oncol Date: 2021-09-30 Impact factor: 54.433
Authors: Giandomenico Roviello; Maria Rosa Cappelletti; Laura Zanotti; Angela Gobbi; Chiara Senti; Alberto Bottini; Andrea Ravelli; Alberto Bonetta; Giovanni Paganini; Daniele Generali Journal: Medicine (Baltimore) Date: 2016-10 Impact factor: 1.889
Authors: K Fizazi; T W Flaig; M Stöckle; H I Scher; J S de Bono; D E Rathkopf; C J Ryan; T Kheoh; J Li; M B Todd; T W Griffin; A Molina; C H Ohlmann Journal: Ann Oncol Date: 2015-11-25 Impact factor: 32.976